Aptus Capital Advisors LLC Acquires 911 Shares of CME Group Inc. (NASDAQ:CME)

Aptus Capital Advisors LLC raised its stake in shares of CME Group Inc. (NASDAQ:CMEFree Report) by 66.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,289 shares of the financial services provider’s stock after purchasing an additional 911 shares during the quarter. Aptus Capital Advisors LLC’s holdings in CME Group were worth $458,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the stock. RB Capital Management LLC grew its holdings in shares of CME Group by 11.4% in the 1st quarter. RB Capital Management LLC now owns 1,419 shares of the financial services provider’s stock worth $338,000 after purchasing an additional 145 shares during the last quarter. Prudential PLC bought a new stake in CME Group during the first quarter worth about $1,709,000. Cetera Investment Advisers increased its holdings in shares of CME Group by 5.8% during the first quarter. Cetera Investment Advisers now owns 3,485 shares of the financial services provider’s stock worth $829,000 after buying an additional 190 shares in the last quarter. Sequoia Financial Advisors LLC bought a new position in shares of CME Group in the first quarter valued at approximately $281,000. Finally, Candriam Luxembourg S.C.A. boosted its holdings in shares of CME Group by 9.5% in the 1st quarter. Candriam Luxembourg S.C.A. now owns 25,230 shares of the financial services provider’s stock worth $6,001,000 after acquiring an additional 2,181 shares in the last quarter. 85.69% of the stock is currently owned by institutional investors.

CME Group Price Performance

CME Group stock opened at $205.09 on Friday. The firm has a market capitalization of $73.83 billion, a P/E ratio of 24.47, a PEG ratio of 2.37 and a beta of 0.48. The business has a 50-day moving average of $207.00 and a 200-day moving average of $207.85. The company has a current ratio of 1.03, a quick ratio of 1.03 and a debt-to-equity ratio of 0.12. CME Group Inc. has a 1 year low of $174.01 and a 1 year high of $223.80.

CME Group Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 26th. Shareholders of record on Friday, March 8th will be issued a $1.15 dividend. The ex-dividend date of this dividend is Thursday, March 7th. This is a positive change from CME Group’s previous quarterly dividend of $1.10. This represents a $4.60 annualized dividend and a yield of 2.24%. CME Group’s dividend payout ratio (DPR) is 52.51%.

Insider Transactions at CME Group

In other CME Group news, insider Derek Sammann sold 10,681 shares of the business’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $220.50, for a total value of $2,355,160.50. Following the completion of the transaction, the insider now directly owns 1,862 shares of the company’s stock, valued at $410,571. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, Director Bryan T. Durkin sold 5,560 shares of the firm’s stock in a transaction on Monday, December 11th. The shares were sold at an average price of $216.37, for a total transaction of $1,203,017.20. Following the sale, the director now directly owns 62,452 shares in the company, valued at $13,512,739.24. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Derek Sammann sold 10,681 shares of the company’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $220.50, for a total transaction of $2,355,160.50. Following the completion of the transaction, the insider now directly owns 1,862 shares of the company’s stock, valued at $410,571. The disclosure for this sale can be found here. Insiders have sold a total of 18,103 shares of company stock valued at $3,971,672 over the last three months. 0.30% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Morgan Stanley lifted their price objective on CME Group from $215.00 to $220.00 and gave the company an “equal weight” rating in a research report on Thursday, October 26th. Rosenblatt Securities reaffirmed a “sell” rating and issued a $180.00 price target on shares of CME Group in a report on Thursday, January 4th. The Goldman Sachs Group lowered shares of CME Group from a “neutral” rating to a “sell” rating and set a $195.00 price objective on the stock. in a report on Wednesday, January 3rd. Finally, Barclays downgraded shares of CME Group from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $244.00 to $222.00 in a research note on Monday, January 8th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, CME Group presently has a consensus rating of “Hold” and a consensus price target of $213.89.

Check Out Our Latest Stock Report on CME

CME Group Company Profile

(Free Report)

CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.

Read More

Institutional Ownership by Quarter for CME Group (NASDAQ:CME)

Receive News & Ratings for CME Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CME Group and related companies with MarketBeat.com's FREE daily email newsletter.